Literature DB >> 22285679

Cardiac autonomic modulation during methadone therapy among heroin users: a pilot study.

Li-Ren Chang1, Yu-Hsuan Lin, Terry B J Kuo, Yen-Cheng Ho, Shiuan-Horng Chen, Hung-Chieh Wu Chang, Chih-Min Liu, Cheryl C H Yang.   

Abstract

BACKGROUND: Methadone therapy benefits heroin users in both the medical and psychosocial dimensions. However, both heroin and methadone have cardiac toxicity. Only limited information is available describing the changes in cardiac autonomic function of heroin users and effects of methadone therapy. We conduct the current study to explore the cardiac vagal function in heroin users as well as the impact of lapse and methadone therapy.
METHODS: 80 heroin users from a methadone therapy clinic were distributed into 31 compliant and 49 incompliant patients according to whether they lapsed into heroin use within 10 days. 40 healthy control subjects were recruited from the community. Participants underwent electrocardiographic recordings and the heroin users were further investigated before and after methadone therapy. Spectral analysis of heart rate variability (HRV) was computed for cardiac parasympathetic modulation (high-frequency power, HF) and cardiac sympathetic modulation (normalized low-frequency power, LF%).
RESULTS: The baseline HRV parameters found lower HF values for heroin users and lower RR interval values for patients with a recent lapse compared with the healthy control subjects. After 1h of methadone administration, heroin users who had lapsed showed a significant increase in HF but the heroin users who had not lapsed did not.
CONCLUSION: Our findings suggest that heroin users show decreased cardiac vagal activity and that methadone therapy immediately facilitates vagal regulation in patients with a recent lapse. The differential patterns of autonomic alteration under methadone between those with and without lapse might offer an objective measure of lapse. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285679     DOI: 10.1016/j.pnpbp.2012.01.006

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

Review 1.  Theoretical implications and clinical support for heart rate variability biofeedback for substance use disorders.

Authors:  Teresa M Leyro; Jennifer F Buckman; Marsha E Bates
Journal:  Curr Opin Psychol       Date:  2019-04-02

Review 2.  Respiratory sinus arrhythmia as a potential measure in substance use treatment--outcome studies.

Authors:  C J Price; S E Crowell
Journal:  Addiction       Date:  2016-01-05       Impact factor: 6.526

Review 3.  Autonomic nervous system dysfunction in psychiatric disorders and the impact of psychotropic medications: a systematic review and meta-analysis.

Authors:  Gail A Alvares; Daniel S Quintana; Ian B Hickie; Adam J Guastella
Journal:  J Psychiatry Neurosci       Date:  2016-03       Impact factor: 6.186

4.  Effect of Heroin on Electrocardiographic Parameters.

Authors:  Ersin Yildirim; Murat Selcuk; Faysal Saylik; Ferit Onur Mutluer; Ozgur Deniz
Journal:  Arq Bras Cardiol       Date:  2020-12       Impact factor: 2.000

5.  Self-reported psychopathology and health-related quality of life in heroin users treated with methadone.

Authors:  Ying-Zai Chen; Wei-Lieh Huang; Jia-Chi Shan; Yu-Hsuan Lin; Hung-Chieh Wu Chang; Li-Ren Chang
Journal:  Neuropsychiatr Dis Treat       Date:  2012-12-27       Impact factor: 2.570

6.  Methadone-mediated autonomic functioning of male patients with heroin dependence: the influence of borderline personality pattern.

Authors:  Wei-Lieh Huang; Yu-Hsuan Lin; Terry B J Kuo; Li-Ren Chang; Ying-Zai Chen; Cheryl C H Yang
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

7.  Heart Rate Variability and the Efficacy of Biofeedback in Heroin Users with Depressive Symptoms.

Authors:  I-Mei Lin; Jiun-Min Ko; Sheng-Yu Fan; Cheng-Fang Yen
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-05-31       Impact factor: 2.582

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.